Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PAX-102
- Development stage
- Preclinical
- Lead developer
- Kuvatris Therapeutics
- Modality
- Small Molecules
- Administration
- Intranasal
01
Overview
**PAX-102** is a proprietary intranasal formulation of suramin sodium, an antipurinergic therapy (APT) developed by PaxMedica for neurodevelopmental disorders. Suramin, historically used for African trypanosomiasis, is repurposed here for its potential to block purinergic receptors, addressing mitochondrial dysfunction and neuroinflammation implicated in conditions like autism spectrum disorder (ASD). PAX-102 targets less severe forms of ASD and other neurologic indications, offering a non-invasive alternative to intravenous suramin (PAX-101), with no FDA-approved therapies currently available for ASD core symptoms.[1][3][4]
- Other names
- intranasal suramin
02
Targets
P2Y (P2Y receptors)
Beyond the preview
Go deeper on PAX-102.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PAX-102.